nodes	percent_of_prediction	percent_of_DWPC	metapath
Doxorubicin—Epirubicin—ovarian cancer	0.191	1	CrCtD
Doxorubicin—Topoisomerase Inhibitors—Topotecan—ovarian cancer	0.113	0.428	CiPCiCtD
Doxorubicin—Anthracyclines—Epirubicin—ovarian cancer	0.0994	0.376	CiPCiCtD
Doxorubicin—uterine cancer—ovarian cancer	0.0552	0.366	CtDrD
Doxorubicin—breast cancer—ovarian cancer	0.0544	0.361	CtDrD
Doxorubicin—Topoisomerase Inhibitors—Epirubicin—ovarian cancer	0.052	0.196	CiPCiCtD
Doxorubicin—CYP1B1—ovarian cancer	0.0501	0.777	CbGaD
Doxorubicin—testicular cancer—ovarian cancer	0.041	0.273	CtDrD
Doxorubicin—Daunorubicin—Epirubicin—ovarian cancer	0.0405	0.333	CrCrCtD
Doxorubicin—Idarubicin—Epirubicin—ovarian cancer	0.0405	0.333	CrCrCtD
Doxorubicin—Valrubicin—Epirubicin—ovarian cancer	0.0405	0.333	CrCrCtD
Doxorubicin—AURKA—Epirubicin—ovarian cancer	0.0214	0.17	CbGbCtD
Doxorubicin—YWHAG—Epirubicin—ovarian cancer	0.0214	0.17	CbGbCtD
Doxorubicin—DHCR7—Epirubicin—ovarian cancer	0.0214	0.17	CbGbCtD
Doxorubicin—ABCB1—ovarian cancer	0.0144	0.223	CbGaD
Doxorubicin—NQO1—Carboplatin—ovarian cancer	0.00905	0.0718	CbGbCtD
Doxorubicin—ABCC10—Paclitaxel—ovarian cancer	0.00615	0.0488	CbGbCtD
Doxorubicin—XDH—Carboplatin—ovarian cancer	0.00473	0.0375	CbGbCtD
Doxorubicin—ABCC10—Docetaxel—ovarian cancer	0.00444	0.0353	CbGbCtD
Doxorubicin—TOP2A—Epirubicin—ovarian cancer	0.00434	0.0344	CbGbCtD
Doxorubicin—ABCB11—Paclitaxel—ovarian cancer	0.00334	0.0265	CbGbCtD
Doxorubicin—CYP1B1—Paclitaxel—ovarian cancer	0.00334	0.0265	CbGbCtD
Doxorubicin—ABCG2—Topotecan—ovarian cancer	0.00321	0.0255	CbGbCtD
Doxorubicin—CYP1B1—Docetaxel—ovarian cancer	0.00241	0.0192	CbGbCtD
Doxorubicin—ABCC1—Epirubicin—ovarian cancer	0.00241	0.0191	CbGbCtD
Doxorubicin—ABCC1—Paclitaxel—ovarian cancer	0.00237	0.0188	CbGbCtD
Doxorubicin—ABCC2—Paclitaxel—ovarian cancer	0.00176	0.0139	CbGbCtD
Doxorubicin—ABCC1—Docetaxel—ovarian cancer	0.00172	0.0136	CbGbCtD
Doxorubicin—ABCC2—Carboplatin—ovarian cancer	0.00165	0.0131	CbGbCtD
Doxorubicin—ABCG2—Paclitaxel—ovarian cancer	0.00159	0.0126	CbGbCtD
Doxorubicin—ABCG2—Carboplatin—ovarian cancer	0.00149	0.0119	CbGbCtD
Doxorubicin—ABCC2—Docetaxel—ovarian cancer	0.00127	0.0101	CbGbCtD
Doxorubicin—ABCB1—Topotecan—ovarian cancer	0.00116	0.00918	CbGbCtD
Doxorubicin—ABCG2—Docetaxel—ovarian cancer	0.00115	0.00911	CbGbCtD
Doxorubicin—ABCB1—Vinorelbine—ovarian cancer	0.000815	0.00647	CbGbCtD
Doxorubicin—CYP2D6—Vinorelbine—ovarian cancer	0.000768	0.00609	CbGbCtD
Doxorubicin—CYP3A4—Topotecan—ovarian cancer	0.000693	0.0055	CbGbCtD
Doxorubicin—NOS3—vein—ovarian cancer	0.000627	0.0318	CbGeAlD
Doxorubicin—ABCB1—Paclitaxel—ovarian cancer	0.000573	0.00454	CbGbCtD
Doxorubicin—Daunorubicin—NR5A1—ovarian cancer	0.000552	0.752	CrCbGaD
Doxorubicin—CYP3A4—Vinorelbine—ovarian cancer	0.000488	0.00387	CbGbCtD
Doxorubicin—ABCB1—Docetaxel—ovarian cancer	0.000414	0.00328	CbGbCtD
Doxorubicin—CYP3A4—Paclitaxel—ovarian cancer	0.000343	0.00272	CbGbCtD
Doxorubicin—CBR3—myometrium—ovarian cancer	0.000277	0.0141	CbGeAlD
Doxorubicin—CBR3—embryo—ovarian cancer	0.000267	0.0135	CbGeAlD
Doxorubicin—CYP3A4—Docetaxel—ovarian cancer	0.000248	0.00197	CbGbCtD
Doxorubicin—SLC22A16—gonad—ovarian cancer	0.000242	0.0123	CbGeAlD
Doxorubicin—SLC22A16—female reproductive system—ovarian cancer	0.000216	0.011	CbGeAlD
Doxorubicin—CBR3—uterine cervix—ovarian cancer	0.000216	0.0109	CbGeAlD
Doxorubicin—AKR1A1—myometrium—ovarian cancer	0.000214	0.0109	CbGeAlD
Doxorubicin—ABCB8—decidua—ovarian cancer	0.000214	0.0108	CbGeAlD
Doxorubicin—CBR3—decidua—ovarian cancer	0.000206	0.0104	CbGeAlD
Doxorubicin—SLC22A16—bone marrow—ovarian cancer	0.000204	0.0103	CbGeAlD
Doxorubicin—CBR3—endometrium—ovarian cancer	0.000195	0.0099	CbGeAlD
Doxorubicin—ABCB8—gonad—ovarian cancer	0.000188	0.00954	CbGeAlD
Doxorubicin—AURKA—myometrium—ovarian cancer	0.000181	0.00917	CbGeAlD
Doxorubicin—SLC22A16—testis—ovarian cancer	0.000174	0.00884	CbGeAlD
Doxorubicin—ABCB8—female reproductive system—ovarian cancer	0.000168	0.00852	CbGeAlD
Doxorubicin—AKR1A1—uterine cervix—ovarian cancer	0.000167	0.00845	CbGeAlD
Doxorubicin—CBR3—female reproductive system—ovarian cancer	0.000162	0.0082	CbGeAlD
Doxorubicin—NDUFS2—myometrium—ovarian cancer	0.000161	0.00818	CbGeAlD
Doxorubicin—NDUFS3—myometrium—ovarian cancer	0.000159	0.00808	CbGeAlD
Doxorubicin—AKR1A1—decidua—ovarian cancer	0.000159	0.00805	CbGeAlD
Doxorubicin—ABCB8—female gonad—ovarian cancer	0.000153	0.00775	CbGeAlD
Doxorubicin—NDUFS7—uterine cervix—ovarian cancer	0.000151	0.00768	CbGeAlD
Doxorubicin—AKR1A1—endometrium—ovarian cancer	0.000151	0.00764	CbGeAlD
Doxorubicin—CBR3—female gonad—ovarian cancer	0.000147	0.00746	CbGeAlD
Doxorubicin—CBR3—vagina—ovarian cancer	0.000146	0.00741	CbGeAlD
Doxorubicin—Daunorubicin—CYP1B1—ovarian cancer	0.000142	0.193	CrCbGaD
Doxorubicin—AURKA—uterine cervix—ovarian cancer	0.000141	0.00714	CbGeAlD
Doxorubicin—AKR1A1—gonad—ovarian cancer	0.00014	0.00709	CbGeAlD
Doxorubicin—AKR1A1—uterus—ovarian cancer	0.000139	0.00704	CbGeAlD
Doxorubicin—YWHAG—myometrium—ovarian cancer	0.000139	0.00704	CbGeAlD
Doxorubicin—ABCB8—testis—ovarian cancer	0.000136	0.00687	CbGeAlD
Doxorubicin—AURKA—Chlorambucil—Melphalan—ovarian cancer	0.000132	0.177	CbGdCrCtD
Doxorubicin—CBR3—testis—ovarian cancer	0.00013	0.00662	CbGeAlD
Doxorubicin—NOS1—epithelium—ovarian cancer	0.000127	0.00646	CbGeAlD
Doxorubicin—AURKA—endometrium—ovarian cancer	0.000127	0.00646	CbGeAlD
Doxorubicin—NDUFS2—uterine cervix—ovarian cancer	0.000125	0.00636	CbGeAlD
Doxorubicin—RALBP1—myometrium—ovarian cancer	0.000125	0.00636	CbGeAlD
Doxorubicin—AKR1A1—female reproductive system—ovarian cancer	0.000125	0.00633	CbGeAlD
Doxorubicin—NDUFS3—uterine cervix—ovarian cancer	0.000124	0.00628	CbGeAlD
Doxorubicin—NDUFS2—decidua—ovarian cancer	0.00012	0.00606	CbGeAlD
Doxorubicin—AURKA—gonad—ovarian cancer	0.000118	0.00599	CbGeAlD
Doxorubicin—NDUFS3—decidua—ovarian cancer	0.000118	0.00599	CbGeAlD
Doxorubicin—AKR1A1—bone marrow—ovarian cancer	0.000118	0.00598	CbGeAlD
Doxorubicin—DHCR7—uterine cervix—ovarian cancer	0.000118	0.00597	CbGeAlD
Doxorubicin—AURKA—uterus—ovarian cancer	0.000117	0.00595	CbGeAlD
Doxorubicin—CBR1—myometrium—ovarian cancer	0.000117	0.00594	CbGeAlD
Doxorubicin—AKR1C3—myometrium—ovarian cancer	0.000116	0.00586	CbGeAlD
Doxorubicin—AKR1A1—female gonad—ovarian cancer	0.000114	0.00576	CbGeAlD
Doxorubicin—NDUFS2—endometrium—ovarian cancer	0.000113	0.00575	CbGeAlD
Doxorubicin—NDUFS7—female reproductive system—ovarian cancer	0.000113	0.00575	CbGeAlD
Doxorubicin—AKR1A1—vagina—ovarian cancer	0.000113	0.00572	CbGeAlD
Doxorubicin—NDUFS3—endometrium—ovarian cancer	0.000112	0.00568	CbGeAlD
Doxorubicin—YWHAG—uterine cervix—ovarian cancer	0.000108	0.00548	CbGeAlD
Doxorubicin—NDUFS7—bone marrow—ovarian cancer	0.000107	0.00543	CbGeAlD
Doxorubicin—NOS1—gonad—ovarian cancer	0.000106	0.00537	CbGeAlD
Doxorubicin—POR—myometrium—ovarian cancer	0.000106	0.00535	CbGeAlD
Doxorubicin—AURKA—female reproductive system—ovarian cancer	0.000105	0.00535	CbGeAlD
Doxorubicin—XDH—uterine cervix—ovarian cancer	0.000105	0.00534	CbGeAlD
Doxorubicin—NDUFS2—gonad—ovarian cancer	0.000105	0.00534	CbGeAlD
Doxorubicin—NDUFS2—uterus—ovarian cancer	0.000105	0.0053	CbGeAlD
Doxorubicin—NDUFS3—gonad—ovarian cancer	0.000104	0.00527	CbGeAlD
Doxorubicin—NDUFS3—uterus—ovarian cancer	0.000103	0.00524	CbGeAlD
Doxorubicin—NDUFS7—female gonad—ovarian cancer	0.000103	0.00523	CbGeAlD
Doxorubicin—YWHAG—decidua—ovarian cancer	0.000103	0.00522	CbGeAlD
Doxorubicin—NDUFS7—vagina—ovarian cancer	0.000103	0.0052	CbGeAlD
Doxorubicin—AKR1A1—testis—ovarian cancer	0.000101	0.00511	CbGeAlD
Doxorubicin—AURKA—bone marrow—ovarian cancer	9.96e-05	0.00505	CbGeAlD
Doxorubicin—DHCR7—gonad—ovarian cancer	9.88e-05	0.00501	CbGeAlD
Doxorubicin—TOP2A—myometrium—ovarian cancer	9.84e-05	0.00499	CbGeAlD
Doxorubicin—ABCB8—lymph node—ovarian cancer	9.83e-05	0.00498	CbGeAlD
Doxorubicin—YWHAG—endometrium—ovarian cancer	9.77e-05	0.00496	CbGeAlD
Doxorubicin—RALBP1—uterine cervix—ovarian cancer	9.76e-05	0.00495	CbGeAlD
Doxorubicin—NOS3—epithelium—ovarian cancer	9.68e-05	0.00491	CbGeAlD
Doxorubicin—AURKA—female gonad—ovarian cancer	9.6e-05	0.00487	CbGeAlD
Doxorubicin—AURKA—vagina—ovarian cancer	9.54e-05	0.00484	CbGeAlD
Doxorubicin—XDH—endometrium—ovarian cancer	9.53e-05	0.00483	CbGeAlD
Doxorubicin—NOS1—female reproductive system—ovarian cancer	9.46e-05	0.0048	CbGeAlD
Doxorubicin—CBR3—lymph node—ovarian cancer	9.46e-05	0.0048	CbGeAlD
Doxorubicin—NDUFS2—female reproductive system—ovarian cancer	9.4e-05	0.00477	CbGeAlD
Doxorubicin—NQO1—myometrium—ovarian cancer	9.38e-05	0.00476	CbGeAlD
Doxorubicin—RALBP1—decidua—ovarian cancer	9.3e-05	0.00471	CbGeAlD
Doxorubicin—NDUFS3—female reproductive system—ovarian cancer	9.29e-05	0.00471	CbGeAlD
Doxorubicin—NDUFS7—testis—ovarian cancer	9.16e-05	0.00464	CbGeAlD
Doxorubicin—AURKA—Irinotecan—Topotecan—ovarian cancer	9.14e-05	0.123	CbGdCrCtD
Doxorubicin—CBR1—uterine cervix—ovarian cancer	9.11e-05	0.00462	CbGeAlD
Doxorubicin—YWHAG—gonad—ovarian cancer	9.07e-05	0.0046	CbGeAlD
Doxorubicin—YWHAG—uterus—ovarian cancer	9.01e-05	0.00457	CbGeAlD
Doxorubicin—AKR1C3—uterine cervix—ovarian cancer	9e-05	0.00456	CbGeAlD
Doxorubicin—NDUFS2—bone marrow—ovarian cancer	8.88e-05	0.0045	CbGeAlD
Doxorubicin—RALBP1—endometrium—ovarian cancer	8.83e-05	0.00448	CbGeAlD
Doxorubicin—DHCR7—female reproductive system—ovarian cancer	8.82e-05	0.00447	CbGeAlD
Doxorubicin—NDUFS3—bone marrow—ovarian cancer	8.77e-05	0.00445	CbGeAlD
Doxorubicin—CBR1—decidua—ovarian cancer	8.68e-05	0.0044	CbGeAlD
Doxorubicin—AKR1C3—decidua—ovarian cancer	8.57e-05	0.00435	CbGeAlD
Doxorubicin—NDUFS2—female gonad—ovarian cancer	8.56e-05	0.00434	CbGeAlD
Doxorubicin—AURKA—testis—ovarian cancer	8.51e-05	0.00432	CbGeAlD
Doxorubicin—NDUFS2—vagina—ovarian cancer	8.5e-05	0.00431	CbGeAlD
Doxorubicin—NDUFS3—female gonad—ovarian cancer	8.45e-05	0.00428	CbGeAlD
Doxorubicin—NQO1—Vincristine—Vinorelbine—ovarian cancer	8.45e-05	0.113	CbGdCrCtD
Doxorubicin—NDUFS3—vagina—ovarian cancer	8.4e-05	0.00426	CbGeAlD
Doxorubicin—ABCC10—myometrium—ovarian cancer	8.38e-05	0.00425	CbGeAlD
Doxorubicin—DHCR7—bone marrow—ovarian cancer	8.33e-05	0.00422	CbGeAlD
Doxorubicin—CBR1—endometrium—ovarian cancer	8.24e-05	0.00418	CbGeAlD
Doxorubicin—POR—uterine cervix—ovarian cancer	8.22e-05	0.00417	CbGeAlD
Doxorubicin—AKR1C3—endometrium—ovarian cancer	8.14e-05	0.00413	CbGeAlD
Doxorubicin—RALBP1—uterus—ovarian cancer	8.13e-05	0.00412	CbGeAlD
Doxorubicin—YWHAG—female reproductive system—ovarian cancer	8.1e-05	0.00411	CbGeAlD
Doxorubicin—DHCR7—female gonad—ovarian cancer	8.03e-05	0.00407	CbGeAlD
Doxorubicin—DHCR7—vagina—ovarian cancer	7.98e-05	0.00405	CbGeAlD
Doxorubicin—XDH—female reproductive system—ovarian cancer	7.9e-05	0.004	CbGeAlD
Doxorubicin—POR—decidua—ovarian cancer	7.83e-05	0.00397	CbGeAlD
Doxorubicin—TOP2A—uterine cervix—ovarian cancer	7.66e-05	0.00388	CbGeAlD
Doxorubicin—YWHAG—bone marrow—ovarian cancer	7.64e-05	0.00388	CbGeAlD
Doxorubicin—CBR1—gonad—ovarian cancer	7.64e-05	0.00388	CbGeAlD
Doxorubicin—NOS1—testis—ovarian cancer	7.64e-05	0.00387	CbGeAlD
Doxorubicin—CBR1—uterus—ovarian cancer	7.59e-05	0.00385	CbGeAlD
Doxorubicin—NDUFS2—testis—ovarian cancer	7.59e-05	0.00385	CbGeAlD
Doxorubicin—AKR1C3—uterus—ovarian cancer	7.5e-05	0.0038	CbGeAlD
Doxorubicin—NDUFS3—testis—ovarian cancer	7.49e-05	0.0038	CbGeAlD
Doxorubicin—POR—endometrium—ovarian cancer	7.43e-05	0.00377	CbGeAlD
Doxorubicin—YWHAG—female gonad—ovarian cancer	7.37e-05	0.00374	CbGeAlD
Doxorubicin—NQO1—epithelium—ovarian cancer	7.36e-05	0.00373	CbGeAlD
Doxorubicin—YWHAG—vagina—ovarian cancer	7.32e-05	0.00371	CbGeAlD
Doxorubicin—RALBP1—female reproductive system—ovarian cancer	7.31e-05	0.00371	CbGeAlD
Doxorubicin—AKR1A1—lymph node—ovarian cancer	7.3e-05	0.0037	CbGeAlD
Doxorubicin—NQO1—uterine cervix—ovarian cancer	7.3e-05	0.0037	CbGeAlD
Doxorubicin—TOP2A—decidua—ovarian cancer	7.3e-05	0.0037	CbGeAlD
Doxorubicin—NOS3—female reproductive system—ovarian cancer	7.19e-05	0.00365	CbGeAlD
Doxorubicin—XDH—vagina—ovarian cancer	7.14e-05	0.00362	CbGeAlD
Doxorubicin—DHCR7—testis—ovarian cancer	7.12e-05	0.00361	CbGeAlD
Doxorubicin—NQO1—decidua—ovarian cancer	6.95e-05	0.00353	CbGeAlD
Doxorubicin—TOP2A—endometrium—ovarian cancer	6.93e-05	0.00351	CbGeAlD
Doxorubicin—RALBP1—bone marrow—ovarian cancer	6.9e-05	0.0035	CbGeAlD
Doxorubicin—CBR1—female reproductive system—ovarian cancer	6.83e-05	0.00346	CbGeAlD
Doxorubicin—AKR1C3—Vincristine—Vinorelbine—ovarian cancer	6.75e-05	0.0906	CbGdCrCtD
Doxorubicin—RALBP1—female gonad—ovarian cancer	6.65e-05	0.00337	CbGeAlD
Doxorubicin—NDUFS7—lymph node—ovarian cancer	6.64e-05	0.00337	CbGeAlD
Doxorubicin—RALBP1—vagina—ovarian cancer	6.61e-05	0.00335	CbGeAlD
Doxorubicin—NQO1—endometrium—ovarian cancer	6.6e-05	0.00335	CbGeAlD
Doxorubicin—YWHAG—testis—ovarian cancer	6.53e-05	0.00331	CbGeAlD
Doxorubicin—ABCC10—uterine cervix—ovarian cancer	6.52e-05	0.00331	CbGeAlD
Doxorubicin—NOS3—vagina—ovarian cancer	6.51e-05	0.0033	CbGeAlD
Doxorubicin—CBR1—bone marrow—ovarian cancer	6.44e-05	0.00327	CbGeAlD
Doxorubicin—TOP2A—uterus—ovarian cancer	6.38e-05	0.00324	CbGeAlD
Doxorubicin—AKR1C3—bone marrow—ovarian cancer	6.36e-05	0.00323	CbGeAlD
Doxorubicin—ABCC3—decidua—ovarian cancer	6.24e-05	0.00316	CbGeAlD
Doxorubicin—ABCB11—testis—ovarian cancer	6.22e-05	0.00316	CbGeAlD
Doxorubicin—ABCC10—decidua—ovarian cancer	6.21e-05	0.00315	CbGeAlD
Doxorubicin—CBR1—female gonad—ovarian cancer	6.21e-05	0.00315	CbGeAlD
Doxorubicin—CBR1—vagina—ovarian cancer	6.17e-05	0.00313	CbGeAlD
Doxorubicin—AURKA—lymph node—ovarian cancer	6.17e-05	0.00313	CbGeAlD
Doxorubicin—AKR1C3—female gonad—ovarian cancer	6.13e-05	0.00311	CbGeAlD
Doxorubicin—AKR1C3—vagina—ovarian cancer	6.1e-05	0.00309	CbGeAlD
Doxorubicin—NQO1—uterus—ovarian cancer	6.08e-05	0.00308	CbGeAlD
Doxorubicin—ABCC1—myometrium—ovarian cancer	5.93e-05	0.003	CbGeAlD
Doxorubicin—RALBP1—testis—ovarian cancer	5.9e-05	0.00299	CbGeAlD
Doxorubicin—ABCC10—endometrium—ovarian cancer	5.9e-05	0.00299	CbGeAlD
Doxorubicin—POR—bone marrow—ovarian cancer	5.81e-05	0.00295	CbGeAlD
Doxorubicin—NOS3—testis—ovarian cancer	5.81e-05	0.00294	CbGeAlD
Doxorubicin—POR—female gonad—ovarian cancer	5.6e-05	0.00284	CbGeAlD
Doxorubicin—POR—vagina—ovarian cancer	5.57e-05	0.00282	CbGeAlD
Doxorubicin—CBR1—testis—ovarian cancer	5.51e-05	0.00279	CbGeAlD
Doxorubicin—NDUFS2—lymph node—ovarian cancer	5.5e-05	0.00279	CbGeAlD
Doxorubicin—ABCC10—gonad—ovarian cancer	5.47e-05	0.00277	CbGeAlD
Doxorubicin—NQO1—female reproductive system—ovarian cancer	5.47e-05	0.00277	CbGeAlD
Doxorubicin—AKR1C3—testis—ovarian cancer	5.44e-05	0.00276	CbGeAlD
Doxorubicin—ABCC10—uterus—ovarian cancer	5.43e-05	0.00275	CbGeAlD
Doxorubicin—NDUFS3—lymph node—ovarian cancer	5.43e-05	0.00275	CbGeAlD
Doxorubicin—AKR1C3—Vinblastine—Vinorelbine—ovarian cancer	5.43e-05	0.0729	CbGdCrCtD
Doxorubicin—TOP2A—bone marrow—ovarian cancer	5.42e-05	0.00275	CbGeAlD
Doxorubicin—TOP2A—female gonad—ovarian cancer	5.22e-05	0.00265	CbGeAlD
Doxorubicin—TOP2A—vagina—ovarian cancer	5.19e-05	0.00263	CbGeAlD
Doxorubicin—DHCR7—lymph node—ovarian cancer	5.16e-05	0.00262	CbGeAlD
Doxorubicin—CBR1—Vincristine—Vinorelbine—ovarian cancer	5.15e-05	0.0692	CbGdCrCtD
Doxorubicin—NQO1—female gonad—ovarian cancer	4.98e-05	0.00252	CbGeAlD
Doxorubicin—POR—testis—ovarian cancer	4.97e-05	0.00252	CbGeAlD
Doxorubicin—NQO1—vagina—ovarian cancer	4.95e-05	0.00251	CbGeAlD
Doxorubicin—ABCC3—female reproductive system—ovarian cancer	4.91e-05	0.00249	CbGeAlD
Doxorubicin—ABCG2—myometrium—ovarian cancer	4.91e-05	0.00249	CbGeAlD
Doxorubicin—ABCC10—female reproductive system—ovarian cancer	4.88e-05	0.00248	CbGeAlD
Doxorubicin—CYP1B1—decidua—ovarian cancer	4.88e-05	0.00248	CbGeAlD
Doxorubicin—YWHAG—lymph node—ovarian cancer	4.74e-05	0.0024	CbGeAlD
Doxorubicin—TOP2A—testis—ovarian cancer	4.63e-05	0.00235	CbGeAlD
Doxorubicin—ABCC10—bone marrow—ovarian cancer	4.61e-05	0.00234	CbGeAlD
Doxorubicin—ABCC1—uterine cervix—ovarian cancer	4.61e-05	0.00234	CbGeAlD
Doxorubicin—ABCC3—female gonad—ovarian cancer	4.47e-05	0.00226	CbGeAlD
Doxorubicin—ABCC10—female gonad—ovarian cancer	4.44e-05	0.00225	CbGeAlD
Doxorubicin—ABCC10—vagina—ovarian cancer	4.42e-05	0.00224	CbGeAlD
Doxorubicin—NQO1—testis—ovarian cancer	4.41e-05	0.00224	CbGeAlD
Doxorubicin—ABCC1—decidua—ovarian cancer	4.39e-05	0.00223	CbGeAlD
Doxorubicin—CYP1B1—gonad—ovarian cancer	4.3e-05	0.00218	CbGeAlD
Doxorubicin—RALBP1—lymph node—ovarian cancer	4.28e-05	0.00217	CbGeAlD
Doxorubicin—CYP1B1—uterus—ovarian cancer	4.27e-05	0.00217	CbGeAlD
Doxorubicin—NOS3—lymph node—ovarian cancer	4.21e-05	0.00213	CbGeAlD
Doxorubicin—ABCC1—endometrium—ovarian cancer	4.17e-05	0.00211	CbGeAlD
Doxorubicin—TOP2A—Docetaxel—Paclitaxel—ovarian cancer	4.08e-05	0.0548	CbGdCrCtD
Doxorubicin—Daunorubicin—ABCB1—ovarian cancer	4.06e-05	0.0553	CrCbGaD
Doxorubicin—CBR1—lymph node—ovarian cancer	3.99e-05	0.00202	CbGeAlD
Doxorubicin—ABCC3—testis—ovarian cancer	3.96e-05	0.00201	CbGeAlD
Doxorubicin—AKR1C3—lymph node—ovarian cancer	3.94e-05	0.002	CbGeAlD
Doxorubicin—ABCC10—testis—ovarian cancer	3.94e-05	0.002	CbGeAlD
Doxorubicin—ABCC2—female reproductive system—ovarian cancer	3.92e-05	0.00199	CbGeAlD
Doxorubicin—ABCC1—uterus—ovarian cancer	3.84e-05	0.00195	CbGeAlD
Doxorubicin—CYP1B1—female reproductive system—ovarian cancer	3.84e-05	0.00195	CbGeAlD
Doxorubicin—ABCG2—uterine cervix—ovarian cancer	3.82e-05	0.00194	CbGeAlD
Doxorubicin—ABCG2—decidua—ovarian cancer	3.64e-05	0.00184	CbGeAlD
Doxorubicin—POR—lymph node—ovarian cancer	3.6e-05	0.00183	CbGeAlD
Doxorubicin—CYP1B1—female gonad—ovarian cancer	3.49e-05	0.00177	CbGeAlD
Doxorubicin—TOP2A—Irinotecan—Topotecan—ovarian cancer	3.49e-05	0.0469	CbGdCrCtD
Doxorubicin—ABCG2—endometrium—ovarian cancer	3.45e-05	0.00175	CbGeAlD
Doxorubicin—CBR3—Idarubicin—Epirubicin—ovarian cancer	3.39e-05	0.0455	CbGdCrCtD
Doxorubicin—CBR3—Daunorubicin—Epirubicin—ovarian cancer	3.39e-05	0.0455	CbGdCrCtD
Doxorubicin—TOP2A—lymph node—ovarian cancer	3.36e-05	0.0017	CbGeAlD
Doxorubicin—NQO1—lymph node—ovarian cancer	3.2e-05	0.00162	CbGeAlD
Doxorubicin—ABCG2—uterus—ovarian cancer	3.18e-05	0.00161	CbGeAlD
Doxorubicin—ABCC2—testis—ovarian cancer	3.17e-05	0.0016	CbGeAlD
Doxorubicin—ABCC1—female gonad—ovarian cancer	3.14e-05	0.00159	CbGeAlD
Doxorubicin—ABCC1—vagina—ovarian cancer	3.12e-05	0.00158	CbGeAlD
Doxorubicin—CYP1B1—testis—ovarian cancer	3.1e-05	0.00157	CbGeAlD
Doxorubicin—CYP2B6—gonad—ovarian cancer	2.95e-05	0.0015	CbGeAlD
Doxorubicin—ABCC3—lymph node—ovarian cancer	2.87e-05	0.00146	CbGeAlD
Doxorubicin—ABCC10—lymph node—ovarian cancer	2.86e-05	0.00145	CbGeAlD
Doxorubicin—ABCC1—testis—ovarian cancer	2.79e-05	0.00141	CbGeAlD
Doxorubicin—ABCG2—bone marrow—ovarian cancer	2.7e-05	0.00137	CbGeAlD
Doxorubicin—CYP2B6—female reproductive system—ovarian cancer	2.64e-05	0.00134	CbGeAlD
Doxorubicin—ABCG2—female gonad—ovarian cancer	2.6e-05	0.00132	CbGeAlD
Doxorubicin—TOP2A—Vindesine—Vinorelbine—ovarian cancer	2.59e-05	0.0348	CbGdCrCtD
Doxorubicin—ABCG2—vagina—ovarian cancer	2.59e-05	0.00131	CbGeAlD
Doxorubicin—ABCB1—myometrium—ovarian cancer	2.42e-05	0.00123	CbGeAlD
Doxorubicin—CYP2B6—vagina—ovarian cancer	2.39e-05	0.00121	CbGeAlD
Doxorubicin—ABCB1—embryo—ovarian cancer	2.33e-05	0.00118	CbGeAlD
Doxorubicin—ABCG2—testis—ovarian cancer	2.31e-05	0.00117	CbGeAlD
Doxorubicin—ABCC2—lymph node—ovarian cancer	2.29e-05	0.00116	CbGeAlD
Doxorubicin—CYP1B1—lymph node—ovarian cancer	2.25e-05	0.00114	CbGeAlD
Doxorubicin—CYP2B6—testis—ovarian cancer	2.13e-05	0.00108	CbGeAlD
Doxorubicin—TOP2A—Paclitaxel—Docetaxel—ovarian cancer	2.04e-05	0.0273	CbGdCrCtD
Doxorubicin—ABCC1—lymph node—ovarian cancer	2.02e-05	0.00102	CbGeAlD
Doxorubicin—CYP3A4—female reproductive system—ovarian cancer	1.99e-05	0.00101	CbGeAlD
Doxorubicin—CYP2D6—female reproductive system—ovarian cancer	1.96e-05	0.000994	CbGeAlD
Doxorubicin—ABCB1—epithelium—ovarian cancer	1.9e-05	0.000963	CbGeAlD
Doxorubicin—ABCB1—uterine cervix—ovarian cancer	1.88e-05	0.000954	CbGeAlD
Doxorubicin—ABCB1—decidua—ovarian cancer	1.79e-05	0.000909	CbGeAlD
Doxorubicin—AURKA—Daunorubicin—Epirubicin—ovarian cancer	1.79e-05	0.024	CbGdCrCtD
Doxorubicin—AURKA—Idarubicin—Epirubicin—ovarian cancer	1.79e-05	0.024	CbGdCrCtD
Doxorubicin—CYP2D6—female gonad—ovarian cancer	1.78e-05	0.000905	CbGeAlD
Doxorubicin—ABCB1—endometrium—ovarian cancer	1.7e-05	0.000863	CbGeAlD
Doxorubicin—ABCG2—lymph node—ovarian cancer	1.67e-05	0.000848	CbGeAlD
Doxorubicin—CYP2D6—testis—ovarian cancer	1.58e-05	0.000802	CbGeAlD
Doxorubicin—ABCB1—gonad—ovarian cancer	1.58e-05	0.000801	CbGeAlD
Doxorubicin—ABCB1—uterus—ovarian cancer	1.57e-05	0.000795	CbGeAlD
Doxorubicin—ABCB1—female reproductive system—ovarian cancer	1.41e-05	0.000715	CbGeAlD
Doxorubicin—TOP2A—Vincristine—Vinorelbine—ovarian cancer	1.4e-05	0.0188	CbGdCrCtD
Doxorubicin—ABCB1—bone marrow—ovarian cancer	1.33e-05	0.000675	CbGeAlD
Doxorubicin—ABCB1—female gonad—ovarian cancer	1.28e-05	0.000651	CbGeAlD
Doxorubicin—ABCB1—vagina—ovarian cancer	1.28e-05	0.000647	CbGeAlD
Doxorubicin—ABCB1—testis—ovarian cancer	1.14e-05	0.000577	CbGeAlD
Doxorubicin—TOP2A—Vinblastine—Vinorelbine—ovarian cancer	1.13e-05	0.0151	CbGdCrCtD
Doxorubicin—ABCB1—lymph node—ovarian cancer	8.25e-06	0.000418	CbGeAlD
Doxorubicin—Asthenia—Vinorelbine—ovarian cancer	7.44e-06	0.000183	CcSEcCtD
Doxorubicin—Dry skin—Epirubicin—ovarian cancer	7.44e-06	0.000183	CcSEcCtD
Doxorubicin—Arrhythmia—Docetaxel—ovarian cancer	7.43e-06	0.000183	CcSEcCtD
Doxorubicin—Orthostatic hypotension—Epirubicin—ovarian cancer	7.41e-06	0.000182	CcSEcCtD
Doxorubicin—Abdominal pain upper—Epirubicin—ovarian cancer	7.41e-06	0.000182	CcSEcCtD
Doxorubicin—Convulsion—Paclitaxel—ovarian cancer	7.41e-06	0.000182	CcSEcCtD
Doxorubicin—Hypokalaemia—Epirubicin—ovarian cancer	7.38e-06	0.000182	CcSEcCtD
Doxorubicin—Hypertension—Paclitaxel—ovarian cancer	7.38e-06	0.000182	CcSEcCtD
Doxorubicin—Alopecia—Docetaxel—ovarian cancer	7.35e-06	0.000181	CcSEcCtD
Doxorubicin—Pruritus—Vinorelbine—ovarian cancer	7.34e-06	0.00018	CcSEcCtD
Doxorubicin—Breast disorder—Epirubicin—ovarian cancer	7.33e-06	0.00018	CcSEcCtD
Doxorubicin—Toxic epidermal necrolysis—Epirubicin—ovarian cancer	7.31e-06	0.00018	CcSEcCtD
Doxorubicin—Aspartate aminotransferase increased—Epirubicin—ovarian cancer	7.31e-06	0.00018	CcSEcCtD
Doxorubicin—Mental disorder—Docetaxel—ovarian cancer	7.29e-06	0.000179	CcSEcCtD
Doxorubicin—Arthralgia—Paclitaxel—ovarian cancer	7.28e-06	0.000179	CcSEcCtD
Doxorubicin—Myalgia—Paclitaxel—ovarian cancer	7.28e-06	0.000179	CcSEcCtD
Doxorubicin—Chest pain—Paclitaxel—ovarian cancer	7.28e-06	0.000179	CcSEcCtD
Doxorubicin—Nasopharyngitis—Epirubicin—ovarian cancer	7.26e-06	0.000178	CcSEcCtD
Doxorubicin—Anxiety—Paclitaxel—ovarian cancer	7.25e-06	0.000178	CcSEcCtD
Doxorubicin—Malnutrition—Docetaxel—ovarian cancer	7.24e-06	0.000178	CcSEcCtD
Doxorubicin—Erythema—Docetaxel—ovarian cancer	7.24e-06	0.000178	CcSEcCtD
Doxorubicin—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	7.23e-06	0.000178	CcSEcCtD
Doxorubicin—Nausea—Topotecan—ovarian cancer	7.2e-06	0.000177	CcSEcCtD
Doxorubicin—Discomfort—Paclitaxel—ovarian cancer	7.19e-06	0.000177	CcSEcCtD
Doxorubicin—Gastritis—Epirubicin—ovarian cancer	7.18e-06	0.000177	CcSEcCtD
Doxorubicin—Muscular weakness—Epirubicin—ovarian cancer	7.16e-06	0.000176	CcSEcCtD
Doxorubicin—Alanine aminotransferase increased—Epirubicin—ovarian cancer	7.16e-06	0.000176	CcSEcCtD
Doxorubicin—Dry mouth—Paclitaxel—ovarian cancer	7.12e-06	0.000175	CcSEcCtD
Doxorubicin—Diarrhoea—Vinorelbine—ovarian cancer	7.1e-06	0.000175	CcSEcCtD
Doxorubicin—Dysgeusia—Docetaxel—ovarian cancer	7.09e-06	0.000175	CcSEcCtD
Doxorubicin—Abdominal distension—Epirubicin—ovarian cancer	7.06e-06	0.000174	CcSEcCtD
Doxorubicin—Nausea—Melphalan—ovarian cancer	7.05e-06	0.000173	CcSEcCtD
Doxorubicin—Confusional state—Paclitaxel—ovarian cancer	7.03e-06	0.000173	CcSEcCtD
Doxorubicin—Asthma—Epirubicin—ovarian cancer	7.01e-06	0.000173	CcSEcCtD
Doxorubicin—Influenza—Epirubicin—ovarian cancer	7.01e-06	0.000173	CcSEcCtD
Doxorubicin—Dysphagia—Epirubicin—ovarian cancer	7.01e-06	0.000173	CcSEcCtD
Doxorubicin—Back pain—Docetaxel—ovarian cancer	7.01e-06	0.000172	CcSEcCtD
Doxorubicin—Anaphylactic shock—Paclitaxel—ovarian cancer	6.98e-06	0.000172	CcSEcCtD
Doxorubicin—Oedema—Paclitaxel—ovarian cancer	6.98e-06	0.000172	CcSEcCtD
Doxorubicin—Muscle spasms—Docetaxel—ovarian cancer	6.97e-06	0.000171	CcSEcCtD
Doxorubicin—Eosinophilia—Epirubicin—ovarian cancer	6.94e-06	0.000171	CcSEcCtD
Doxorubicin—Infection—Paclitaxel—ovarian cancer	6.93e-06	0.00017	CcSEcCtD
Doxorubicin—Pancreatitis—Epirubicin—ovarian cancer	6.88e-06	0.000169	CcSEcCtD
Doxorubicin—Shock—Paclitaxel—ovarian cancer	6.86e-06	0.000169	CcSEcCtD
Doxorubicin—Dizziness—Vinorelbine—ovarian cancer	6.86e-06	0.000169	CcSEcCtD
Doxorubicin—Nervous system disorder—Paclitaxel—ovarian cancer	6.84e-06	0.000168	CcSEcCtD
Doxorubicin—Angina pectoris—Epirubicin—ovarian cancer	6.83e-06	0.000168	CcSEcCtD
Doxorubicin—Thrombocytopenia—Paclitaxel—ovarian cancer	6.83e-06	0.000168	CcSEcCtD
Doxorubicin—TOP2A—Daunorubicin—Epirubicin—ovarian cancer	6.82e-06	0.00915	CbGdCrCtD
Doxorubicin—TOP2A—Idarubicin—Epirubicin—ovarian cancer	6.82e-06	0.00915	CbGdCrCtD
Doxorubicin—Tachycardia—Paclitaxel—ovarian cancer	6.81e-06	0.000167	CcSEcCtD
Doxorubicin—Skin disorder—Paclitaxel—ovarian cancer	6.78e-06	0.000167	CcSEcCtD
Doxorubicin—Bronchitis—Epirubicin—ovarian cancer	6.74e-06	0.000166	CcSEcCtD
Doxorubicin—Hyperhidrosis—Paclitaxel—ovarian cancer	6.74e-06	0.000166	CcSEcCtD
Doxorubicin—Anaemia—Docetaxel—ovarian cancer	6.7e-06	0.000165	CcSEcCtD
Doxorubicin—Pancytopenia—Epirubicin—ovarian cancer	6.66e-06	0.000164	CcSEcCtD
Doxorubicin—Anorexia—Paclitaxel—ovarian cancer	6.65e-06	0.000164	CcSEcCtD
Doxorubicin—Vomiting—Vinorelbine—ovarian cancer	6.59e-06	0.000162	CcSEcCtD
Doxorubicin—Dysuria—Epirubicin—ovarian cancer	6.56e-06	0.000161	CcSEcCtD
Doxorubicin—Neutropenia—Epirubicin—ovarian cancer	6.56e-06	0.000161	CcSEcCtD
Doxorubicin—Rash—Vinorelbine—ovarian cancer	6.54e-06	0.000161	CcSEcCtD
Doxorubicin—Dermatitis—Vinorelbine—ovarian cancer	6.53e-06	0.000161	CcSEcCtD
Doxorubicin—Hypotension—Paclitaxel—ovarian cancer	6.52e-06	0.00016	CcSEcCtD
Doxorubicin—Upper respiratory tract infection—Epirubicin—ovarian cancer	6.52e-06	0.00016	CcSEcCtD
Doxorubicin—Headache—Vinorelbine—ovarian cancer	6.5e-06	0.00016	CcSEcCtD
Doxorubicin—Syncope—Docetaxel—ovarian cancer	6.5e-06	0.00016	CcSEcCtD
Doxorubicin—Leukopenia—Docetaxel—ovarian cancer	6.48e-06	0.00016	CcSEcCtD
Doxorubicin—Pollakiuria—Epirubicin—ovarian cancer	6.48e-06	0.000159	CcSEcCtD
Doxorubicin—Palpitations—Docetaxel—ovarian cancer	6.4e-06	0.000157	CcSEcCtD
Doxorubicin—Photosensitivity reaction—Epirubicin—ovarian cancer	6.4e-06	0.000157	CcSEcCtD
Doxorubicin—Weight increased—Epirubicin—ovarian cancer	6.38e-06	0.000157	CcSEcCtD
Doxorubicin—Loss of consciousness—Docetaxel—ovarian cancer	6.37e-06	0.000157	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	6.36e-06	0.000156	CcSEcCtD
Doxorubicin—Weight decreased—Epirubicin—ovarian cancer	6.34e-06	0.000156	CcSEcCtD
Doxorubicin—Hyperglycaemia—Epirubicin—ovarian cancer	6.33e-06	0.000156	CcSEcCtD
Doxorubicin—Cough—Docetaxel—ovarian cancer	6.32e-06	0.000156	CcSEcCtD
Doxorubicin—Insomnia—Paclitaxel—ovarian cancer	6.31e-06	0.000155	CcSEcCtD
Doxorubicin—Pneumonia—Epirubicin—ovarian cancer	6.29e-06	0.000155	CcSEcCtD
Doxorubicin—Convulsion—Docetaxel—ovarian cancer	6.28e-06	0.000154	CcSEcCtD
Doxorubicin—Paraesthesia—Paclitaxel—ovarian cancer	6.26e-06	0.000154	CcSEcCtD
Doxorubicin—Hypertension—Docetaxel—ovarian cancer	6.25e-06	0.000154	CcSEcCtD
Doxorubicin—Drowsiness—Epirubicin—ovarian cancer	6.25e-06	0.000154	CcSEcCtD
Doxorubicin—Infestation NOS—Epirubicin—ovarian cancer	6.25e-06	0.000154	CcSEcCtD
Doxorubicin—Infestation—Epirubicin—ovarian cancer	6.25e-06	0.000154	CcSEcCtD
Doxorubicin—Dyspnoea—Paclitaxel—ovarian cancer	6.22e-06	0.000153	CcSEcCtD
Doxorubicin—Somnolence—Paclitaxel—ovarian cancer	6.2e-06	0.000153	CcSEcCtD
Doxorubicin—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	6.2e-06	0.000152	CcSEcCtD
Doxorubicin—Chest pain—Docetaxel—ovarian cancer	6.17e-06	0.000152	CcSEcCtD
Doxorubicin—Arthralgia—Docetaxel—ovarian cancer	6.17e-06	0.000152	CcSEcCtD
Doxorubicin—Myalgia—Docetaxel—ovarian cancer	6.17e-06	0.000152	CcSEcCtD
Doxorubicin—Nausea—Vinorelbine—ovarian cancer	6.16e-06	0.000152	CcSEcCtD
Doxorubicin—Renal failure—Epirubicin—ovarian cancer	6.15e-06	0.000151	CcSEcCtD
Doxorubicin—Dyspepsia—Paclitaxel—ovarian cancer	6.14e-06	0.000151	CcSEcCtD
Doxorubicin—Neuropathy peripheral—Epirubicin—ovarian cancer	6.13e-06	0.000151	CcSEcCtD
Doxorubicin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	6.13e-06	0.000151	CcSEcCtD
Doxorubicin—Jaundice—Epirubicin—ovarian cancer	6.1e-06	0.00015	CcSEcCtD
Doxorubicin—Stomatitis—Epirubicin—ovarian cancer	6.1e-06	0.00015	CcSEcCtD
Doxorubicin—Urinary tract infection—Epirubicin—ovarian cancer	6.08e-06	0.00015	CcSEcCtD
Doxorubicin—Conjunctivitis—Epirubicin—ovarian cancer	6.08e-06	0.00015	CcSEcCtD
Doxorubicin—Decreased appetite—Paclitaxel—ovarian cancer	6.06e-06	0.000149	CcSEcCtD
Doxorubicin—Dry mouth—Docetaxel—ovarian cancer	6.03e-06	0.000148	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Paclitaxel—ovarian cancer	6.02e-06	0.000148	CcSEcCtD
Doxorubicin—Fatigue—Paclitaxel—ovarian cancer	6.01e-06	0.000148	CcSEcCtD
Doxorubicin—Sweating—Epirubicin—ovarian cancer	5.99e-06	0.000147	CcSEcCtD
Doxorubicin—Pain—Paclitaxel—ovarian cancer	5.97e-06	0.000147	CcSEcCtD
Doxorubicin—Constipation—Paclitaxel—ovarian cancer	5.97e-06	0.000147	CcSEcCtD
Doxorubicin—Haematuria—Epirubicin—ovarian cancer	5.96e-06	0.000147	CcSEcCtD
Doxorubicin—Confusional state—Docetaxel—ovarian cancer	5.96e-06	0.000147	CcSEcCtD
Doxorubicin—Hepatobiliary disease—Epirubicin—ovarian cancer	5.91e-06	0.000145	CcSEcCtD
Doxorubicin—Anaphylactic shock—Docetaxel—ovarian cancer	5.91e-06	0.000145	CcSEcCtD
Doxorubicin—Oedema—Docetaxel—ovarian cancer	5.91e-06	0.000145	CcSEcCtD
Doxorubicin—Epistaxis—Epirubicin—ovarian cancer	5.9e-06	0.000145	CcSEcCtD
Doxorubicin—Infection—Docetaxel—ovarian cancer	5.87e-06	0.000144	CcSEcCtD
Doxorubicin—Sinusitis—Epirubicin—ovarian cancer	5.87e-06	0.000144	CcSEcCtD
Doxorubicin—Agranulocytosis—Epirubicin—ovarian cancer	5.84e-06	0.000144	CcSEcCtD
Doxorubicin—Shock—Docetaxel—ovarian cancer	5.82e-06	0.000143	CcSEcCtD
Doxorubicin—Nervous system disorder—Docetaxel—ovarian cancer	5.8e-06	0.000143	CcSEcCtD
Doxorubicin—Thrombocytopenia—Docetaxel—ovarian cancer	5.79e-06	0.000142	CcSEcCtD
Doxorubicin—Tachycardia—Docetaxel—ovarian cancer	5.77e-06	0.000142	CcSEcCtD
Doxorubicin—Feeling abnormal—Paclitaxel—ovarian cancer	5.75e-06	0.000141	CcSEcCtD
Doxorubicin—Skin disorder—Docetaxel—ovarian cancer	5.74e-06	0.000141	CcSEcCtD
Doxorubicin—Bradycardia—Epirubicin—ovarian cancer	5.71e-06	0.000141	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Paclitaxel—ovarian cancer	5.7e-06	0.00014	CcSEcCtD
Doxorubicin—Haemoglobin—Epirubicin—ovarian cancer	5.64e-06	0.000139	CcSEcCtD
Doxorubicin—Anorexia—Docetaxel—ovarian cancer	5.64e-06	0.000139	CcSEcCtD
Doxorubicin—Rhinitis—Epirubicin—ovarian cancer	5.63e-06	0.000138	CcSEcCtD
Doxorubicin—Haemorrhage—Epirubicin—ovarian cancer	5.61e-06	0.000138	CcSEcCtD
Doxorubicin—Hepatitis—Epirubicin—ovarian cancer	5.61e-06	0.000138	CcSEcCtD
Doxorubicin—Hypoaesthesia—Epirubicin—ovarian cancer	5.59e-06	0.000137	CcSEcCtD
Doxorubicin—Pharyngitis—Epirubicin—ovarian cancer	5.57e-06	0.000137	CcSEcCtD
Doxorubicin—Urinary tract disorder—Epirubicin—ovarian cancer	5.54e-06	0.000136	CcSEcCtD
Doxorubicin—Urticaria—Paclitaxel—ovarian cancer	5.54e-06	0.000136	CcSEcCtD
Doxorubicin—Oedema peripheral—Epirubicin—ovarian cancer	5.53e-06	0.000136	CcSEcCtD
Doxorubicin—Hypotension—Docetaxel—ovarian cancer	5.52e-06	0.000136	CcSEcCtD
Doxorubicin—Connective tissue disorder—Epirubicin—ovarian cancer	5.52e-06	0.000136	CcSEcCtD
Doxorubicin—Abdominal pain—Paclitaxel—ovarian cancer	5.51e-06	0.000136	CcSEcCtD
Doxorubicin—Body temperature increased—Paclitaxel—ovarian cancer	5.51e-06	0.000136	CcSEcCtD
Doxorubicin—Urethral disorder—Epirubicin—ovarian cancer	5.5e-06	0.000135	CcSEcCtD
Doxorubicin—Visual impairment—Epirubicin—ovarian cancer	5.41e-06	0.000133	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Docetaxel—ovarian cancer	5.39e-06	0.000133	CcSEcCtD
Doxorubicin—Insomnia—Docetaxel—ovarian cancer	5.35e-06	0.000132	CcSEcCtD
Doxorubicin—Paraesthesia—Docetaxel—ovarian cancer	5.31e-06	0.000131	CcSEcCtD
Doxorubicin—Erythema multiforme—Epirubicin—ovarian cancer	5.31e-06	0.000131	CcSEcCtD
Doxorubicin—Dyspnoea—Docetaxel—ovarian cancer	5.27e-06	0.00013	CcSEcCtD
Doxorubicin—Somnolence—Docetaxel—ovarian cancer	5.26e-06	0.000129	CcSEcCtD
Doxorubicin—Eye disorder—Epirubicin—ovarian cancer	5.25e-06	0.000129	CcSEcCtD
Doxorubicin—Tinnitus—Epirubicin—ovarian cancer	5.23e-06	0.000129	CcSEcCtD
Doxorubicin—Flushing—Epirubicin—ovarian cancer	5.21e-06	0.000128	CcSEcCtD
Doxorubicin—Cardiac disorder—Epirubicin—ovarian cancer	5.21e-06	0.000128	CcSEcCtD
Doxorubicin—Dyspepsia—Docetaxel—ovarian cancer	5.2e-06	0.000128	CcSEcCtD
Doxorubicin—Decreased appetite—Docetaxel—ovarian cancer	5.14e-06	0.000126	CcSEcCtD
Doxorubicin—Hypersensitivity—Paclitaxel—ovarian cancer	5.14e-06	0.000126	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Docetaxel—ovarian cancer	5.1e-06	0.000126	CcSEcCtD
Doxorubicin—Fatigue—Docetaxel—ovarian cancer	5.1e-06	0.000125	CcSEcCtD
Doxorubicin—Angiopathy—Epirubicin—ovarian cancer	5.09e-06	0.000125	CcSEcCtD
Doxorubicin—Immune system disorder—Epirubicin—ovarian cancer	5.07e-06	0.000125	CcSEcCtD
Doxorubicin—Mediastinal disorder—Epirubicin—ovarian cancer	5.06e-06	0.000124	CcSEcCtD
Doxorubicin—Pain—Docetaxel—ovarian cancer	5.06e-06	0.000124	CcSEcCtD
Doxorubicin—Constipation—Docetaxel—ovarian cancer	5.06e-06	0.000124	CcSEcCtD
Doxorubicin—Chills—Epirubicin—ovarian cancer	5.04e-06	0.000124	CcSEcCtD
Doxorubicin—Arrhythmia—Epirubicin—ovarian cancer	5.01e-06	0.000123	CcSEcCtD
Doxorubicin—Asthenia—Paclitaxel—ovarian cancer	5e-06	0.000123	CcSEcCtD
Doxorubicin—Alopecia—Epirubicin—ovarian cancer	4.96e-06	0.000122	CcSEcCtD
Doxorubicin—Pruritus—Paclitaxel—ovarian cancer	4.94e-06	0.000121	CcSEcCtD
Doxorubicin—Mental disorder—Epirubicin—ovarian cancer	4.92e-06	0.000121	CcSEcCtD
Doxorubicin—Erythema—Epirubicin—ovarian cancer	4.89e-06	0.00012	CcSEcCtD
Doxorubicin—Malnutrition—Epirubicin—ovarian cancer	4.89e-06	0.00012	CcSEcCtD
Doxorubicin—Feeling abnormal—Docetaxel—ovarian cancer	4.87e-06	0.00012	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Docetaxel—ovarian cancer	4.83e-06	0.000119	CcSEcCtD
Doxorubicin—Flatulence—Epirubicin—ovarian cancer	4.82e-06	0.000118	CcSEcCtD
Doxorubicin—Tension—Epirubicin—ovarian cancer	4.8e-06	0.000118	CcSEcCtD
Doxorubicin—Dysgeusia—Epirubicin—ovarian cancer	4.79e-06	0.000118	CcSEcCtD
Doxorubicin—Diarrhoea—Paclitaxel—ovarian cancer	4.77e-06	0.000117	CcSEcCtD
Doxorubicin—Nervousness—Epirubicin—ovarian cancer	4.75e-06	0.000117	CcSEcCtD
Doxorubicin—Back pain—Epirubicin—ovarian cancer	4.73e-06	0.000116	CcSEcCtD
Doxorubicin—Muscle spasms—Epirubicin—ovarian cancer	4.7e-06	0.000116	CcSEcCtD
Doxorubicin—Abdominal pain—Docetaxel—ovarian cancer	4.67e-06	0.000115	CcSEcCtD
Doxorubicin—Body temperature increased—Docetaxel—ovarian cancer	4.67e-06	0.000115	CcSEcCtD
Doxorubicin—Dizziness—Paclitaxel—ovarian cancer	4.61e-06	0.000113	CcSEcCtD
Doxorubicin—Vision blurred—Epirubicin—ovarian cancer	4.61e-06	0.000113	CcSEcCtD
Doxorubicin—Ill-defined disorder—Epirubicin—ovarian cancer	4.53e-06	0.000112	CcSEcCtD
Doxorubicin—Anaemia—Epirubicin—ovarian cancer	4.52e-06	0.000111	CcSEcCtD
Doxorubicin—Agitation—Epirubicin—ovarian cancer	4.49e-06	0.00011	CcSEcCtD
Doxorubicin—Vomiting—Paclitaxel—ovarian cancer	4.44e-06	0.000109	CcSEcCtD
Doxorubicin—Malaise—Epirubicin—ovarian cancer	4.41e-06	0.000108	CcSEcCtD
Doxorubicin—Rash—Paclitaxel—ovarian cancer	4.4e-06	0.000108	CcSEcCtD
Doxorubicin—Dermatitis—Paclitaxel—ovarian cancer	4.39e-06	0.000108	CcSEcCtD
Doxorubicin—Vertigo—Epirubicin—ovarian cancer	4.39e-06	0.000108	CcSEcCtD
Doxorubicin—Syncope—Epirubicin—ovarian cancer	4.38e-06	0.000108	CcSEcCtD
Doxorubicin—Leukopenia—Epirubicin—ovarian cancer	4.37e-06	0.000108	CcSEcCtD
Doxorubicin—Headache—Paclitaxel—ovarian cancer	4.37e-06	0.000107	CcSEcCtD
Doxorubicin—Hypersensitivity—Docetaxel—ovarian cancer	4.36e-06	0.000107	CcSEcCtD
Doxorubicin—Palpitations—Epirubicin—ovarian cancer	4.32e-06	0.000106	CcSEcCtD
Doxorubicin—Loss of consciousness—Epirubicin—ovarian cancer	4.29e-06	0.000106	CcSEcCtD
Doxorubicin—Cough—Epirubicin—ovarian cancer	4.26e-06	0.000105	CcSEcCtD
Doxorubicin—Asthenia—Docetaxel—ovarian cancer	4.24e-06	0.000104	CcSEcCtD
Doxorubicin—Convulsion—Epirubicin—ovarian cancer	4.23e-06	0.000104	CcSEcCtD
Doxorubicin—Hypertension—Epirubicin—ovarian cancer	4.22e-06	0.000104	CcSEcCtD
Doxorubicin—Pruritus—Docetaxel—ovarian cancer	4.18e-06	0.000103	CcSEcCtD
Doxorubicin—Chest pain—Epirubicin—ovarian cancer	4.16e-06	0.000102	CcSEcCtD
Doxorubicin—Arthralgia—Epirubicin—ovarian cancer	4.16e-06	0.000102	CcSEcCtD
Doxorubicin—Myalgia—Epirubicin—ovarian cancer	4.16e-06	0.000102	CcSEcCtD
Doxorubicin—Anxiety—Epirubicin—ovarian cancer	4.15e-06	0.000102	CcSEcCtD
Doxorubicin—Nausea—Paclitaxel—ovarian cancer	4.14e-06	0.000102	CcSEcCtD
Doxorubicin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	4.13e-06	0.000102	CcSEcCtD
Doxorubicin—Discomfort—Epirubicin—ovarian cancer	4.11e-06	0.000101	CcSEcCtD
Doxorubicin—Dry mouth—Epirubicin—ovarian cancer	4.07e-06	0.0001	CcSEcCtD
Doxorubicin—Diarrhoea—Docetaxel—ovarian cancer	4.05e-06	9.95e-05	CcSEcCtD
Doxorubicin—Confusional state—Epirubicin—ovarian cancer	4.02e-06	9.89e-05	CcSEcCtD
Doxorubicin—Oedema—Epirubicin—ovarian cancer	3.99e-06	9.81e-05	CcSEcCtD
Doxorubicin—Anaphylactic shock—Epirubicin—ovarian cancer	3.99e-06	9.81e-05	CcSEcCtD
Doxorubicin—Infection—Epirubicin—ovarian cancer	3.96e-06	9.75e-05	CcSEcCtD
Doxorubicin—Shock—Epirubicin—ovarian cancer	3.92e-06	9.65e-05	CcSEcCtD
Doxorubicin—Nervous system disorder—Epirubicin—ovarian cancer	3.91e-06	9.62e-05	CcSEcCtD
Doxorubicin—Dizziness—Docetaxel—ovarian cancer	3.91e-06	9.62e-05	CcSEcCtD
Doxorubicin—Thrombocytopenia—Epirubicin—ovarian cancer	3.9e-06	9.6e-05	CcSEcCtD
Doxorubicin—Tachycardia—Epirubicin—ovarian cancer	3.89e-06	9.57e-05	CcSEcCtD
Doxorubicin—Skin disorder—Epirubicin—ovarian cancer	3.87e-06	9.53e-05	CcSEcCtD
Doxorubicin—Hyperhidrosis—Epirubicin—ovarian cancer	3.86e-06	9.48e-05	CcSEcCtD
Doxorubicin—Anorexia—Epirubicin—ovarian cancer	3.8e-06	9.35e-05	CcSEcCtD
Doxorubicin—Vomiting—Docetaxel—ovarian cancer	3.76e-06	9.25e-05	CcSEcCtD
Doxorubicin—Rash—Docetaxel—ovarian cancer	3.73e-06	9.17e-05	CcSEcCtD
Doxorubicin—Hypotension—Epirubicin—ovarian cancer	3.73e-06	9.17e-05	CcSEcCtD
Doxorubicin—Dermatitis—Docetaxel—ovarian cancer	3.72e-06	9.16e-05	CcSEcCtD
Doxorubicin—Headache—Docetaxel—ovarian cancer	3.7e-06	9.11e-05	CcSEcCtD
Doxorubicin—Musculoskeletal discomfort—Epirubicin—ovarian cancer	3.63e-06	8.94e-05	CcSEcCtD
Doxorubicin—Insomnia—Epirubicin—ovarian cancer	3.61e-06	8.87e-05	CcSEcCtD
Doxorubicin—Paraesthesia—Epirubicin—ovarian cancer	3.58e-06	8.81e-05	CcSEcCtD
Doxorubicin—Dyspnoea—Epirubicin—ovarian cancer	3.56e-06	8.75e-05	CcSEcCtD
Doxorubicin—Somnolence—Epirubicin—ovarian cancer	3.55e-06	8.72e-05	CcSEcCtD
Doxorubicin—Nausea—Docetaxel—ovarian cancer	3.51e-06	8.64e-05	CcSEcCtD
Doxorubicin—Dyspepsia—Epirubicin—ovarian cancer	3.51e-06	8.64e-05	CcSEcCtD
Doxorubicin—Decreased appetite—Epirubicin—ovarian cancer	3.47e-06	8.53e-05	CcSEcCtD
Doxorubicin—Gastrointestinal disorder—Epirubicin—ovarian cancer	3.44e-06	8.47e-05	CcSEcCtD
Doxorubicin—Fatigue—Epirubicin—ovarian cancer	3.44e-06	8.46e-05	CcSEcCtD
Doxorubicin—Constipation—Epirubicin—ovarian cancer	3.41e-06	8.39e-05	CcSEcCtD
Doxorubicin—Pain—Epirubicin—ovarian cancer	3.41e-06	8.39e-05	CcSEcCtD
Doxorubicin—Feeling abnormal—Epirubicin—ovarian cancer	3.29e-06	8.08e-05	CcSEcCtD
Doxorubicin—Gastrointestinal pain—Epirubicin—ovarian cancer	3.26e-06	8.02e-05	CcSEcCtD
Doxorubicin—Urticaria—Epirubicin—ovarian cancer	3.17e-06	7.79e-05	CcSEcCtD
Doxorubicin—Abdominal pain—Epirubicin—ovarian cancer	3.15e-06	7.75e-05	CcSEcCtD
Doxorubicin—Body temperature increased—Epirubicin—ovarian cancer	3.15e-06	7.75e-05	CcSEcCtD
Doxorubicin—Hypersensitivity—Epirubicin—ovarian cancer	2.94e-06	7.23e-05	CcSEcCtD
Doxorubicin—Asthenia—Epirubicin—ovarian cancer	2.86e-06	7.04e-05	CcSEcCtD
Doxorubicin—Pruritus—Epirubicin—ovarian cancer	2.82e-06	6.94e-05	CcSEcCtD
Doxorubicin—Diarrhoea—Epirubicin—ovarian cancer	2.73e-06	6.71e-05	CcSEcCtD
Doxorubicin—Dizziness—Epirubicin—ovarian cancer	2.64e-06	6.49e-05	CcSEcCtD
Doxorubicin—Vomiting—Epirubicin—ovarian cancer	2.54e-06	6.24e-05	CcSEcCtD
Doxorubicin—Rash—Epirubicin—ovarian cancer	2.51e-06	6.19e-05	CcSEcCtD
Doxorubicin—Dermatitis—Epirubicin—ovarian cancer	2.51e-06	6.18e-05	CcSEcCtD
Doxorubicin—Headache—Epirubicin—ovarian cancer	2.5e-06	6.15e-05	CcSEcCtD
Doxorubicin—Nausea—Epirubicin—ovarian cancer	2.37e-06	5.83e-05	CcSEcCtD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	1.15e-06	5.79e-05	CbGpPWpGaD
Doxorubicin—NOS1—Disease—HRAS—ovarian cancer	1.15e-06	5.79e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PPP2R1A—ovarian cancer	1.15e-06	5.78e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—PIK3CD—ovarian cancer	1.15e-06	5.77e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.15e-06	5.75e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—IL6ST—ovarian cancer	1.14e-06	5.71e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—MAPK3—ovarian cancer	1.14e-06	5.71e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—PIK3CD—ovarian cancer	1.14e-06	5.71e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—TERT—ovarian cancer	1.13e-06	5.67e-05	CbGpPWpGaD
Doxorubicin—DHCR7—Metabolism—AKT1—ovarian cancer	1.13e-06	5.64e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—CDKN1B—ovarian cancer	1.12e-06	5.64e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	1.12e-06	5.63e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—CAV1—ovarian cancer	1.12e-06	5.61e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.11e-06	5.59e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—MYC—ovarian cancer	1.11e-06	5.56e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—ABCB1—ovarian cancer	1.11e-06	5.55e-05	CbGpPWpGaD
Doxorubicin—NOS1—Disease—IL6—ovarian cancer	1.1e-06	5.54e-05	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—PIK3CB—ovarian cancer	1.1e-06	5.54e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	1.1e-06	5.51e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	1.1e-06	5.51e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—STAT3—ovarian cancer	1.1e-06	5.49e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—APC—ovarian cancer	1.09e-06	5.49e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—PIK3CG—ovarian cancer	1.09e-06	5.49e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—NRAS—ovarian cancer	1.09e-06	5.48e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—PIK3CA—ovarian cancer	1.09e-06	5.48e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—TYMS—ovarian cancer	1.09e-06	5.45e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—MAPK1—ovarian cancer	1.08e-06	5.44e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—EGFR—ovarian cancer	1.08e-06	5.43e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—ABCB1—ovarian cancer	1.07e-06	5.37e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.07e-06	5.36e-05	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—PTEN—ovarian cancer	1.06e-06	5.33e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—CTNNB1—ovarian cancer	1.06e-06	5.33e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—PIK3CG—ovarian cancer	1.06e-06	5.33e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—TP53—ovarian cancer	1.06e-06	5.3e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—TYMS—ovarian cancer	1.05e-06	5.27e-05	CbGpPWpGaD
Doxorubicin—CBR1—Metabolism—AKT1—ovarian cancer	1.05e-06	5.26e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PPP2R1A—ovarian cancer	1.05e-06	5.26e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—MAPK3—ovarian cancer	1.05e-06	5.25e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—CAV1—ovarian cancer	1.05e-06	5.24e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	1.04e-06	5.2e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—PTEN—ovarian cancer	1.04e-06	5.19e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—PTEN—ovarian cancer	1.03e-06	5.15e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—KRAS—ovarian cancer	1.02e-06	5.13e-05	CbGpPWpGaD
Doxorubicin—NOS1—Disease—AKT1—ovarian cancer	1.02e-06	5.11e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—PIK3CG—ovarian cancer	1.02e-06	5.11e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—MYC—ovarian cancer	1.02e-06	5.11e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—HRAS—ovarian cancer	1.01e-06	5.07e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—ERBB2—ovarian cancer	1.01e-06	5.05e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—PIK3CB—ovarian cancer	1e-06	5.03e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—MAPK1—ovarian cancer	9.96e-07	4.99e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—EGFR—ovarian cancer	9.96e-07	4.99e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—MTOR—ovarian cancer	9.93e-07	4.98e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—PIK3CB—ovarian cancer	9.93e-07	4.98e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—IL6ST—ovarian cancer	9.92e-07	4.97e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—ABCB1—ovarian cancer	9.74e-07	4.88e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—IL6—ovarian cancer	9.67e-07	4.85e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—PIK3CD—ovarian cancer	9.63e-07	4.83e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—TYMS—ovarian cancer	9.57e-07	4.8e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CXCL8—ovarian cancer	9.54e-07	4.78e-05	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—PTEN—ovarian cancer	9.54e-07	4.78e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	9.53e-07	4.78e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—APC—ovarian cancer	9.53e-07	4.78e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—FASN—ovarian cancer	9.52e-07	4.77e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—KRAS—ovarian cancer	9.41e-07	4.72e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—PIK3CA—ovarian cancer	9.41e-07	4.72e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—SLC5A5—ovarian cancer	9.36e-07	4.7e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—PIK3CD—ovarian cancer	9.34e-07	4.68e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CDKN1B—ovarian cancer	9.32e-07	4.67e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—STAT3—ovarian cancer	9.26e-07	4.64e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—NRAS—ovarian cancer	9.24e-07	4.63e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	9.22e-07	4.63e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CASP3—ovarian cancer	9.13e-07	4.58e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—IL2—ovarian cancer	9.12e-07	4.57e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—CYTB—ovarian cancer	9.05e-07	4.54e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—SLC2A1—ovarian cancer	9.04e-07	4.53e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—PIK3CD—ovarian cancer	8.95e-07	4.49e-05	CbGpPWpGaD
Doxorubicin—RALBP1—Signaling Pathways—AKT1—ovarian cancer	8.92e-07	4.47e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CCND1—ovarian cancer	8.89e-07	4.46e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—MAPK3—ovarian cancer	8.85e-07	4.44e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—CTNNB1—ovarian cancer	8.8e-07	4.41e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—CAV1—ovarian cancer	8.76e-07	4.39e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—HRAS—ovarian cancer	8.7e-07	4.36e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—PTEN—ovarian cancer	8.67e-07	4.35e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—CYP1B1—ovarian cancer	8.67e-07	4.35e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—PIK3CA—ovarian cancer	8.64e-07	4.33e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—MMP9—ovarian cancer	8.63e-07	4.33e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—YAP1—ovarian cancer	8.61e-07	4.32e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—MYC—ovarian cancer	8.6e-07	4.31e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—PTEN—ovarian cancer	8.58e-07	4.3e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—ERBB2—ovarian cancer	8.5e-07	4.26e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—CAV1—ovarian cancer	8.47e-07	4.25e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—MAPK1—ovarian cancer	8.42e-07	4.22e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—EGFR—ovarian cancer	8.41e-07	4.22e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—MTOR—ovarian cancer	8.39e-07	4.21e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—PIK3CB—ovarian cancer	8.39e-07	4.21e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—PIK3CD—ovarian cancer	8.38e-07	4.2e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	8.37e-07	4.2e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—IL6—ovarian cancer	8.33e-07	4.18e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—PIK3CB—ovarian cancer	8.14e-07	4.08e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—YAP1—ovarian cancer	8.12e-07	4.07e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	8.09e-07	4.06e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CXCL8—ovarian cancer	8.06e-07	4.04e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—HRAS—ovarian cancer	8e-07	4.01e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PIK3CG—ovarian cancer	7.98e-07	4e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—KRAS—ovarian cancer	7.95e-07	3.99e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PPP1CC—ovarian cancer	7.91e-07	3.97e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—BRIP1—ovarian cancer	7.91e-07	3.97e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CDKN1B—ovarian cancer	7.87e-07	3.95e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—PIK3CB—ovarian cancer	7.8e-07	3.91e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	7.79e-07	3.91e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—VEGFA—ovarian cancer	7.75e-07	3.89e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PIK3CG—ovarian cancer	7.72e-07	3.87e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CASP3—ovarian cancer	7.72e-07	3.87e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—CAV1—ovarian cancer	7.71e-07	3.87e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—IL2—ovarian cancer	7.7e-07	3.86e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PPP2R1A—ovarian cancer	7.69e-07	3.86e-05	CbGpPWpGaD
Doxorubicin—NOS2—Disease—AKT1—ovarian cancer	7.68e-07	3.85e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—STAT3—ovarian cancer	7.67e-07	3.85e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—NRAS—ovarian cancer	7.65e-07	3.84e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—IL6—ovarian cancer	7.65e-07	3.84e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CCND1—ovarian cancer	7.51e-07	3.77e-05	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—PIK3CA—ovarian cancer	7.5e-07	3.76e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—CTNNB1—ovarian cancer	7.44e-07	3.73e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—ERBB2—ovarian cancer	7.4e-07	3.71e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—MAPK3—ovarian cancer	7.33e-07	3.68e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—PIK3CA—ovarian cancer	7.3e-07	3.66e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—PIK3CB—ovarian cancer	7.3e-07	3.66e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—MTOR—ovarian cancer	7.3e-07	3.66e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—MMP9—ovarian cancer	7.29e-07	3.66e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—PTEN—ovarian cancer	7.25e-07	3.64e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—PIK3CA—ovarian cancer	7.24e-07	3.63e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—ABCB1—ovarian cancer	7.14e-07	3.58e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—MYC—ovarian cancer	7.13e-07	3.58e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Disease—AKT1—ovarian cancer	7.06e-07	3.54e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—PTEN—ovarian cancer	7.03e-07	3.53e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PIK3CG—ovarian cancer	7.02e-07	3.52e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—FASN—ovarian cancer	7.02e-07	3.52e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PIK3CD—ovarian cancer	7.01e-07	3.52e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—TYMS—ovarian cancer	7.01e-07	3.52e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—MAPK1—ovarian cancer	6.98e-07	3.5e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—EGFR—ovarian cancer	6.97e-07	3.5e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—SLC5A5—ovarian cancer	6.91e-07	3.46e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—CDKN1B—ovarian cancer	6.85e-07	3.44e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PIK3CD—ovarian cancer	6.78e-07	3.4e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—HRAS—ovarian cancer	6.76e-07	3.39e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—PTEN—ovarian cancer	6.74e-07	3.38e-05	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—PIK3CA—ovarian cancer	6.73e-07	3.37e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—SLC2A1—ovarian cancer	6.67e-07	3.34e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—FASN—ovarian cancer	6.62e-07	3.32e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—KRAS—ovarian cancer	6.59e-07	3.3e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—VEGFA—ovarian cancer	6.55e-07	3.28e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—SLC5A5—ovarian cancer	6.51e-07	3.26e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—STAT3—ovarian cancer	6.48e-07	3.25e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—CTNNB1—ovarian cancer	6.47e-07	3.25e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—NRAS—ovarian cancer	6.47e-07	3.24e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—IL6—ovarian cancer	6.47e-07	3.24e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—CYP1B1—ovarian cancer	6.39e-07	3.21e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—PTEN—ovarian cancer	6.31e-07	3.16e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—SLC2A1—ovarian cancer	6.29e-07	3.15e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—MAPK3—ovarian cancer	6.19e-07	3.11e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PIK3CD—ovarian cancer	6.17e-07	3.09e-05	CbGpPWpGaD
Doxorubicin—NQO1—Metabolism—AKT1—ovarian cancer	6.13e-07	3.07e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—PIK3CA—ovarian cancer	6.12e-07	3.07e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PIK3CB—ovarian cancer	6.11e-07	3.07e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—PIK3CA—ovarian cancer	6.05e-07	3.04e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—CYP1B1—ovarian cancer	6.03e-07	3.02e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—MYC—ovarian cancer	6.02e-07	3.02e-05	CbGpPWpGaD
Doxorubicin—NOS3—Disease—AKT1—ovarian cancer	5.97e-07	2.99e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Metabolism—AKT1—ovarian cancer	5.91e-07	2.97e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PIK3CB—ovarian cancer	5.91e-07	2.97e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—MAPK1—ovarian cancer	5.89e-07	2.96e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—EGFR—ovarian cancer	5.89e-07	2.95e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—TP53—ovarian cancer	5.86e-07	2.94e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PPP2R1A—ovarian cancer	5.67e-07	2.84e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—CAV1—ovarian cancer	5.65e-07	2.83e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—STAT3—ovarian cancer	5.64e-07	2.83e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—NRAS—ovarian cancer	5.63e-07	2.82e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—HRAS—ovarian cancer	5.6e-07	2.81e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—KRAS—ovarian cancer	5.57e-07	2.79e-05	CbGpPWpGaD
Doxorubicin—XDH—Metabolism—AKT1—ovarian cancer	5.5e-07	2.76e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—MAPK3—ovarian cancer	5.39e-07	2.7e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PIK3CB—ovarian cancer	5.38e-07	2.7e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—IL6—ovarian cancer	5.36e-07	2.69e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	5.34e-07	2.68e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—YAP1—ovarian cancer	5.31e-07	2.66e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PTEN—ovarian cancer	5.28e-07	2.65e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—MYC—ovarian cancer	5.24e-07	2.63e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—TYMS—ovarian cancer	5.17e-07	2.59e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PIK3CG—ovarian cancer	5.15e-07	2.58e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—MAPK1—ovarian cancer	5.13e-07	2.57e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—EGFR—ovarian cancer	5.13e-07	2.57e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—PIK3CA—ovarian cancer	5.11e-07	2.56e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PTEN—ovarian cancer	5.11e-07	2.56e-05	CbGpPWpGaD
Doxorubicin—NOS3—Metabolism—AKT1—ovarian cancer	5e-07	2.51e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—ABCB1—ovarian cancer	4.96e-07	2.49e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—PIK3CA—ovarian cancer	4.96e-07	2.49e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—TP53—ovarian cancer	4.95e-07	2.48e-05	CbGpPWpGaD
Doxorubicin—AKR1C3—Signaling Pathways—AKT1—ovarian cancer	4.94e-07	2.48e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—TYMS—ovarian cancer	4.87e-07	2.44e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—KRAS—ovarian cancer	4.84e-07	2.43e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—PIK3CA—ovarian cancer	4.76e-07	2.39e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—HRAS—ovarian cancer	4.73e-07	2.37e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PTEN—ovarian cancer	4.65e-07	2.33e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—IL6—ovarian cancer	4.53e-07	2.27e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PIK3CD—ovarian cancer	4.52e-07	2.27e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—PIK3CA—ovarian cancer	4.45e-07	2.23e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—FASN—ovarian cancer	4.33e-07	2.17e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—SLC5A5—ovarian cancer	4.25e-07	2.13e-05	CbGpPWpGaD
Doxorubicin—NOS3—Signaling Pathways—AKT1—ovarian cancer	4.18e-07	2.09e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—CAV1—ovarian cancer	4.17e-07	2.09e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—HRAS—ovarian cancer	4.12e-07	2.06e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—SLC2A1—ovarian cancer	4.11e-07	2.06e-05	CbGpPWpGaD
Doxorubicin—ABCB11—Metabolism—AKT1—ovarian cancer	4.05e-07	2.03e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PIK3CB—ovarian cancer	3.94e-07	1.98e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—IL6—ovarian cancer	3.94e-07	1.98e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—CYP1B1—ovarian cancer	3.94e-07	1.98e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—CAV1—ovarian cancer	3.93e-07	1.97e-05	CbGpPWpGaD
Doxorubicin—ABCC3—Metabolism—AKT1—ovarian cancer	3.89e-07	1.95e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PIK3CG—ovarian cancer	3.8e-07	1.9e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—PIK3CA—ovarian cancer	3.73e-07	1.87e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Disease—AKT1—ovarian cancer	3.64e-07	1.82e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—PIK3CA—ovarian cancer	3.6e-07	1.81e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PIK3CG—ovarian cancer	3.58e-07	1.79e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	3.49e-07	1.75e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PTEN—ovarian cancer	3.41e-07	1.71e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PIK3CD—ovarian cancer	3.34e-07	1.67e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—PIK3CA—ovarian cancer	3.28e-07	1.64e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—ABCB1—ovarian cancer	3.24e-07	1.63e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—TYMS—ovarian cancer	3.19e-07	1.6e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PIK3CD—ovarian cancer	3.14e-07	1.58e-05	CbGpPWpGaD
Doxorubicin—ABCC1—Metabolism—AKT1—ovarian cancer	3.04e-07	1.53e-05	CbGpPWpGaD
Doxorubicin—CYP1B1—Metabolism—AKT1—ovarian cancer	2.94e-07	1.48e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PIK3CB—ovarian cancer	2.91e-07	1.46e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PIK3CB—ovarian cancer	2.74e-07	1.37e-05	CbGpPWpGaD
Doxorubicin—ABCG2—Metabolism—AKT1—ovarian cancer	2.68e-07	1.34e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—CAV1—ovarian cancer	2.57e-07	1.29e-05	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PTEN—ovarian cancer	2.51e-07	1.26e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—PIK3CA—ovarian cancer	2.4e-07	1.21e-05	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PTEN—ovarian cancer	2.37e-07	1.19e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PIK3CG—ovarian cancer	2.34e-07	1.17e-05	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PIK3CD—ovarian cancer	2.06e-07	1.03e-05	CbGpPWpGaD
Doxorubicin—CYP2B6—Metabolism—AKT1—ovarian cancer	1.96e-07	9.85e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PIK3CB—ovarian cancer	1.79e-07	8.99e-06	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—PIK3CA—ovarian cancer	1.77e-07	8.89e-06	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—PIK3CA—ovarian cancer	1.67e-07	8.38e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PTEN—ovarian cancer	1.55e-07	7.76e-06	CbGpPWpGaD
Doxorubicin—ABCB1—Metabolism—AKT1—ovarian cancer	1.45e-07	7.26e-06	CbGpPWpGaD
Doxorubicin—CYP2D6—Metabolism—AKT1—ovarian cancer	1.36e-07	6.84e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—PIK3CA—ovarian cancer	1.09e-07	5.48e-06	CbGpPWpGaD
Doxorubicin—CYP3A4—Metabolism—AKT1—ovarian cancer	8.92e-08	4.47e-06	CbGpPWpGaD
